(Q38685600)

5 September 2017

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis (English)

1 reference

5 September 2017

1 reference

Kevin Litchfield

2

0 references

Nicolai Juul Birkbak

Nicolai J Birkbak

15

0 references

Nicholas McGranahan

Nicholas McGranahan

5

0 references

Sherene Loi

Sherene Loi

14

0 references

Charles Swanton

Charles Swanton

20

0 references

Sergio A Quezada

Sergio A Quezada

19

0 references

James L Reading

6

James L Reading

1 reference

5 September 2017

1

Samra Turajlic

1 reference

5 September 2017

11

Tim Chambers

1 reference

5 September 2017

10

Maise Al Bakir

1 reference

5 September 2017

9

Nnennaya Kanu

1 reference

Roberto C Salgado-Delgado

5 September 2017

12

Roberto Salgado

1 reference

5 September 2017

16

Laurent Sansregret

1 reference

5 September 2017

Hang Xu

3

1 reference

5 September 2017

Rachel Rosenthal

4

1 reference

5 September 2017

Yien Ning S Wong

7

1 reference

5 September 2017

Andrew Rowan

8

1 reference

5 September 2017

Peter Savas

13

1 reference

5 September 2017

Martin Gore

17

1 reference

5 September 2017

James Larkin

18

1 reference

5 September 2017

7 July 2017

1 reference

Lancet Oncology Commission

5 September 2017

1 reference

5 September 2017

18

1 reference

5 September 2017

8

1 reference

5 September 2017

1009-1021

1 reference

Tumor neoantigens: building a framework for personalized cancer immunotherapy

5 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

The Cancer Genome Atlas Pan-Cancer analysis project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Important role of indels in somatic mutations of human cancer genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Signatures of mutational processes in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Integrated molecular analysis of clear-cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Tracking the Evolution of Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Fast and accurate short read alignment with Burrows-Wheeler transform

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

The Sequence Alignment/Map format and SAMtools

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Comprehensive molecular characterization of clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

The rules and impact of nonsense-mediated mRNA decay in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

PyClone: statistical inference of clonal population structure in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Allele-specific copy number analysis of tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

HLA-binding properties of tumor neoepitopes in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Frameshift mutations and the genetic code. This paper is dedicated to Professor Theodosius Dobzhansky on the occasion of his 66th birthday

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Renal cell cancer linked to Lynch syndrome: Increased incidence and loss of mismatch repair protein expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Fhit deficiency-induced global genome instability promotes mutation and clonal expansion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

The somatic genomic landscape of chromophobe renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Variation in genomic landscape of clear cell renal cell carcinoma across Europe.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Ochratoxin A induces DNA double-strand breaks and large deletion mutations in the carcinogenic target site of gpt delta rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Transcriptome and genome sequencing uncovers functional variation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Molecular and cellular insights into T cell exhaustion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

OpEx - a validated, automated pipeline optimised for clinical exome sequence analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930516-8

7 January 2021

10.1016/S1470-2045(17)30516-8

Identifiers

DOI

1 reference

5 September 2017

1 reference